March 2, 2018 / 7:42 AM / 5 months ago

BRIEF-Mithra Pharmaceuticals FY Net Loss At 35.0 Million Euros

March 2 (Reuters) - MITHRA PHARMACEUTICALS SA:

* CASH AT DECEMBER 31 2017 WAS EUR 36.2‍​ MILLION VERSUS EUR 45.7 MILLION YEAR AGO

* FY REVENUE EUR 46.3 MILLION VERSUS EUR 22.5 MILLION YEAR AGO

* FY REBITDA LOSS EUR 18.1 MILLION VERSUS LOSS OF EUR 34.9 MILLION YEAR AGO

* FY NET LOSS STABLE AT EUR 35.0 MILLION

* TOWARDS END OF Q1/EARLY Q2, TOP-LINE PHASE II DOSE-FINDING RESULTS FOR DONESTA ARE EXPECTED

* RESULTS OF THE FIRST PIVOTAL ESTELLE STUDY IN THE EU & RUSSIA TO BE AVAILABLE IN Q3 2018

* RESULTS OF ESTELLE STUDY IN US/CANADA PHASE III RESULTS TO BE PUBLISHED IN Q1 2019

* EUROPEAN APPROVAL CAN ALREADY BE EXPECTED IN Q2/Q3 2018 FOR MYRING

* FOR MYRING MAYNE PHARMA MAKING SIGNIFICANT PROGRESS FOR THE US APPROVAL AND LAUNCH, EXPECTED IN H1 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below